ImmunityBio Overview

  • Founded
  • 2014

  • Status
  • Public

  • Employees
  • 688

  • Stock Symbol
  • IBRX

Stock Symbol
  • Investments
  • 6

  • Share Price
  • $3.72

  • (As of Thursday Closing)

ImmunityBio General Information


ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

Contact Information

Formerly Known As
NantCell, NantBioCell
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • 9920 Jefferson Boulevard
  • Culver City, CA 90232
  • United States
+1 (310) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunityBio Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.72 $3.77 $2.60 - $14.59 $1.48B 398M 2.06M -$0.94

ImmunityBio Financials Summary

In Thousands,
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 2,559,089 2,676,511
Revenue 809 934 605 2,202
EBITDA (338,627) (321,588) (205,945) (143,065)
Net Income (370,002) (346,790) (221,851) (157,777)
Total Assets 389,587 468,910 221,381
Total Debt 648,798 645,664 275,547 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ImmunityBio Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ImmunityBio‘s full profile, request access.

Request a free trial

ImmunityBio Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogen
Culver City, CA
688 As of 2022
000000000000 00000


laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000 000000000
Philadelphia, PA
00 As of 0000
0000 0000-00-00
00000000000 00000


usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
San Carlos, CA
000 As of 0000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmunityBio Competitors (71)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tmunity Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
0000000 0000000000 Corporation San Carlos, CA 000 00000 00000000 00000
000000 000 Formerly VC-backed Menlo Park, CA 00 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00 000000000000 Formerly VC-backed Shanghai, China 000 00000 00000000 00000
You’re viewing 5 of 71 competitors. Get the full list »

ImmunityBio Patents

ImmunityBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210283245-A1 Anti covid-19 therapies targeting nucleocapsid and spike proteins Pending 11-Mar-2020 000000000
US-20210284716-A1 Ace2-fc trap Pending 11-Mar-2020 000000000
US-20210284713-A1 Anti covid-19 therapies using cd40 ligand fusion protein Pending 11-Mar-2020 0000000000
US-20210255902-A1 Cloud computing burst instance management Pending 19-Feb-2020 00000000000
US-20210230547-A1 Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors Pending 28-Jan-2020 A61P35/00
To view ImmunityBio’s complete patent history, request access »

ImmunityBio Executive Team (8)

Name Title Board Seat Contact Info
Richard Adcock Chief Executive Officer & Board Member
David Sachs Chief Financial Officer, Finance
Fabio Benedetti MD Chief Strategy Officer
Regan Lauer Chief Accounting Officer, Accounting
Helen Luu Chief Commercial Officer
You’re viewing 5 of 8 executive team members. Get the full list »

ImmunityBio Board Members (8)

Name Representing Role Since
Cheryl Cohen Self Board Member 000 0000
Christobel Selecky Self Board Member 000 0000
Linda Maxwell ImmunityBio Board Member 000 0000
Michael Blaszyk Self Board Member 000 0000
Patrick Soon-Shiong MD ImmunityBio Founder, Executive Chairman & Chief Scientific & Medical Officer 000 0000
You’re viewing 5 of 8 board members. Get the full list »

ImmunityBio Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunityBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ImmunityBio‘s full profile, request access.

Request a free trial

ImmunityBio Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 09-Mar-2021 0000000000 Drug Discovery 0000000 0
00000 0000000 01-Aug-2017 0000000000 000 Drug Discovery 0000000 0
00000000000 23-Mar-2017 0000000000 00.00 Biotechnology 0000000 0
0000000 01-Jan-2016 0000000000 Other Devices and Supplies 0000000 0
Precision Biologics 19-Oct-2015 Merger/Acquisition 0000 Drug Discovery 0000000 0
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

ImmunityBio Subsidiaries (2)

Company Name Industry Location Founded
Etubics Other Devices and Supplies Seattle, WA 2003
00000000000 Biotechnology Louisville, CO 0000
To view ImmunityBio’s complete subsidiaries history, request access »